All companies
Waters Corp logo

What smart money is saying about Waters CorpUnited States flag

WAT · Healthcare · Medical - Diagnostics & Research · Market cap $22.54B

2 funds in our archive have pitched Waters Corp — most recently Artisan U.S. Mid-Cap Growth Strategy in December 2025.

Company profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

Get an email when a fund writes about it

Summarize with Warren AI
8
Reported positions
0
Bought
5
Sold
10
Letters

Position history

Between Q1 2025 and Q2 2026, 8 fund letters reported a position in Waters Corp5 trimmed or exited.

Fund letters reporting a position in Waters Corp, by quarter
QuarterLettersBoughtSoldTheses
Q2 20264030
Q1 20264020
Q4 20250001
Q1 20250001

Fund activity · 8 positions · 5 moves

  • HoldsFindlay Park American Fund
    June 2026
    West Pharmaceutical Services and Waters benefited from accelerating organic revenue growth and improved guidance.
    Read the letterWaters Corp
  • ExitedHarris Associates Global Strategy
    June 2026
    We eliminated the following position(s) during the period:
    Read the letterWaters Corp
  • ExitedClearBridge Investments Dividend Strategy
    June 2026
    We also exited the small position in Waters we had received following its spinoff from Becton Dickinson in the first quarter.
    Read the letterWaters Corp
  • ExitedHarris Associates Global All Cap Strategy
    June 2026
    We eliminated the following position(s) during the period:
    Read the letterWaters Corp
  • Exited1578 Partners, LP
    March 2026
    We sold the shares of WAT we received.
    Read the letterWaters Corp
  • ExitedBrown Advisory Large-Cap Sustainable Value
    March 2026
    We sold our shares in WAT and used the proceeds to add to our existing position in BDX.
    Read the letterWaters Corp
  • HoldsHardman Johnston Large Cap Equity
    March 2026
    Vertex Pharmaceuticals Inc. United States 2.4 Biotechnology Waters Corporation United States 0.3 Life Sciences Tools & Services
    Read the letterWaters Corp
  • HoldsHardman Johnston Select Equity
    March 2026

    Listed in Hardman Johnston Select Equity’s reported holdings.

    Read the letterWaters Corp

Fund coverage · 2 theses

  • Artisan U.S. Mid-Cap Growth Strategy
    December 2025

    Waters provides chromatography and mass spectrometry tools with strong recurring revenue and tailwinds from pharma demand, replacement cycles and biologics exposure.

    Read the full thesis
  • Baron Health Care Fund
    March 2025

    Waters Corporation is a leading provider of analytical instruments with a strong market position in biopharmaceutical quality control, poised for growth driven by various factors, including new regulations and increased demand in multiple sectors.

    Read the full thesis

Read every full thesis on Waters Corp

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger